Managing statin-related side effects: should we avoid or overcome them?

Statins have revolutionized the management of dyslipidemia and remain the first-line therapy for preventing atherosclerotic cardiovascular disease. Despite these advantages, concerns regarding adverse effects, particularly muscle-related symptoms, hepatotoxicity, and new-onset diabetes mellitus, often hinder adherence and compromise cardiovascular protection. This review summarizes current evidence on statin-associated adverse effects and explores strategies to optimize their management. Statin-associated muscle symptoms (SAMS) are the most frequently reported side effects; however, randomized controlled trials demonstrate a low true pharmacologic incidence (<3%). The majority of SAMS are attributable to patient misperception or the nocebo effect. Proper evaluation, including measurement of creatine kinase, dose adjustment, and consideration of alternative lipid-lowering strategies such as ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, may allow patients to resume therapy. Statin therapy is also associated with a modest increase in new-onset diabetes, particularly at higher doses. However, the absolute risk is small and is outweighed by the substantial reduction in cardiovascular events. Hepatotoxicity related to statins is rare, generally mild, and reversible upon discontinuation. Clinically significant adverse effects of statins are uncommon, and most can be managed through careful patient assessment, objective diagnostic evaluation, and appropriate reassurance. Importantly, the cardiovascular benefits of statins far exceed their potential risks. Therefore, rather than avoiding statins because of concerns about side effects, clinicians should adopt evidence-based strategies to overcome these challenges and ensure safe, sustained cardiovascular protection.